Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis

Table 1 Treatment goals and endpoints of chronic hepatitis B guidelines at home and abroad

Guidelines	Time(yr)	Treatment goals	Treatment endpoints
			persistent inhibition of HBV DNA	HBeAg seroconversion		HBsAg clearance
European Association for the Study of the Liver (EASL)	2009	Improve quality of life and survival	Next most desirable endpoint	Satisfactory endpoint		Ideal endpoint
	2012	Improve quality of life and survival	Next most desirable endpoint	Satisfactory endpoint		Ideal endpoint
	2017	Improve survival and quality of life, prevent mother to child transmission	Main endpoint	Valuable endpoint		Optimal endpoint
American Association for the Study of Liver Diseases (AASLD)	2009	Improve prognosis	-	-		-
	2016	Decrease the morbidity and mortality	-	Intermediate endpoint		Best predictor of sustained remission
	2018	Reduce risk of progression to cirrhosis and liver-related complications	-	-		“Functional cure” or “Resolved CHB”
Chinese guidelines for the prevention and treatment of chronic hepatitis B	2005	Improve quality of life and survival	-	-		-
	2010	Improve quality of life and survival	-	-		-
	2015	Improve quality of life and survival	Basic endpoint	Satisfactory endpoint	Ideal endpoint (“clinical cure”)

HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen.